5
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Sarcoidosis is a chronic multisystem disease of unknown etiology, characterized by noncaseating granulomatous infiltration of virtually any organ system. Treatment is often undertaken in an attempt to resolve symptoms or prevent progression to organ failure. Previous studies have suggested a prominent role for tumor necrosis factor-alpha (TNF-α) in the inflammatory process seen in sarcoidosis. TNF-α and interleukin-1 are released by alveolar macrophages in patients with active lung disease. Corticosteroids have proved to be efficacious in the treatment of sarcoidosis, possibly by suppressing the production of TNF-α and other cytokines. Three agents are currently available as specific TNF antagonists: etanercept, infliximab, and adalimumab. Although data from noncomparative trials suggest that all three have comparable therapeutic effects in rheumatoid arthritis, their effects in a granulomatous disease such as sarcoidosis are less consistent. In this review, current data on the effectiveness are summarized.

          Related collections

          Author and article information

          Journal
          Ther Clin Risk Manag
          Therapeutics and Clinical Risk Management
          Therapeutics and Clinical Risk Management
          Dove Medical Press
          1176-6336
          1178-203X
          December 2008
          December 2008
          : 4
          : 6
          : 1305-1313
          Affiliations
          Unit of Autoimmune Systemic Diseases, Hospital Clinico San Cecilio, Granada, Spain
          Author notes
          Correspondence: José Luis Callejas-Rubio, Unit of Autoimmune Systemic Diseases, Hospital Clinico San Cecilio, Avda Dr Olóriz s/n 18007, Granada, Spain, Tel +34 958 023 558, Email jlcalleja@ 123456telefonica.net
          Article
          tcrm-4-1305
          2643111
          19337437
          © 2008 Dove Medical Press Limited. All rights reserved
          Categories
          Review

          Medicine

          sarcoidosis, adalimumab, etanercept, infliximab, anti-tna alpha

          Comments

          Comment on this article